Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)

Alessandro Castriota-Scanderbeg, Michele Sacco

Research output: Contribution to journalArticle

Abstract

A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment. Changes in the humoral and cell-mediated immune function, including antinuclear antibodies (ANA), anti-DNA and extractable-nuclear antigens (ENA) antibodies positivity, increased immunoglobulin values, decreased T suppressor and the presence of circulating immune complexes, suggest a cause-and-effect relationship with the observed clinical manifestations. A careful monitoring of the immune function is recommended in patients who are receiving the oral iron chelator L1.

Original languageEnglish
Pages (from-to)254-255
Number of pages2
JournalBritish Journal of Haematology
Volume96
Issue number2
Publication statusPublished - 1997

Fingerprint

Systemic Vasculitis
Agranulocytosis
Chelating Agents
Arthritis
Iron
Immunologic Monitoring
Antinuclear Antibodies
Antigen-Antibody Complex
Ankle
Immunoglobulins
DNA
deferiprone
Therapeutics
anti-extractable nuclear antigen antibodies

Keywords

  • immune function
  • L1 (deferiprone)
  • thalassaemia major
  • vasculitis

ASJC Scopus subject areas

  • Hematology

Cite this

Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). / Castriota-Scanderbeg, Alessandro; Sacco, Michele.

In: British Journal of Haematology, Vol. 96, No. 2, 1997, p. 254-255.

Research output: Contribution to journalArticle

@article{255a873bacdc489e8c58e1fc7cdc00ea,
title = "Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)",
abstract = "A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment. Changes in the humoral and cell-mediated immune function, including antinuclear antibodies (ANA), anti-DNA and extractable-nuclear antigens (ENA) antibodies positivity, increased immunoglobulin values, decreased T suppressor and the presence of circulating immune complexes, suggest a cause-and-effect relationship with the observed clinical manifestations. A careful monitoring of the immune function is recommended in patients who are receiving the oral iron chelator L1.",
keywords = "immune function, L1 (deferiprone), thalassaemia major, vasculitis",
author = "Alessandro Castriota-Scanderbeg and Michele Sacco",
year = "1997",
language = "English",
volume = "96",
pages = "254--255",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)

AU - Castriota-Scanderbeg, Alessandro

AU - Sacco, Michele

PY - 1997

Y1 - 1997

N2 - A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment. Changes in the humoral and cell-mediated immune function, including antinuclear antibodies (ANA), anti-DNA and extractable-nuclear antigens (ENA) antibodies positivity, increased immunoglobulin values, decreased T suppressor and the presence of circulating immune complexes, suggest a cause-and-effect relationship with the observed clinical manifestations. A careful monitoring of the immune function is recommended in patients who are receiving the oral iron chelator L1.

AB - A thalassaemic girl presented with agranulocytosis, arthritis of both ankles and clinical and laboratory features consistent with the diagnosis of systemic vasculitis, during oral iron chelator L1 (deferiprone) treatment. Changes in the humoral and cell-mediated immune function, including antinuclear antibodies (ANA), anti-DNA and extractable-nuclear antigens (ENA) antibodies positivity, increased immunoglobulin values, decreased T suppressor and the presence of circulating immune complexes, suggest a cause-and-effect relationship with the observed clinical manifestations. A careful monitoring of the immune function is recommended in patients who are receiving the oral iron chelator L1.

KW - immune function

KW - L1 (deferiprone)

KW - thalassaemia major

KW - vasculitis

UR - http://www.scopus.com/inward/record.url?scp=0031046747&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031046747&partnerID=8YFLogxK

M3 - Article

C2 - 9029008

AN - SCOPUS:0031046747

VL - 96

SP - 254

EP - 255

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -